The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Shareholders OK £46 Billion Shire Takeover
December 5, 2018
-
ORGANIZATION 9 EFPIA Companies Reviewed Headcount Planning after Drug Pricing Overhaul: Survey
December 5, 2018
-
BUSINESS Takeda Family Member Comes Forward for Final Appeal to Veto Shire Deal, but Admits Uphill Battle
December 4, 2018
-
BUSINESS With Current R&D Model Reaching Its Limit, Industry Going Digital to Boost Efficiency: Astellas Chairman
December 3, 2018
-
BUSINESS JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
-
BUSINESS Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
November 29, 2018
-
REGULATORY AMED Study Group Drafting Japan’s 1st Guidelines for Development of Recombinant Virus Vaccines
November 29, 2018
-
TRENDS Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
November 28, 2018
-
BUSINESS Keytruda Continues to Close in on Opdivo in July-September Global Sales
November 27, 2018
-
REGULATORY MHLW Proposes Introduction of Administrative Fines for Improperly Earned Revenues
November 27, 2018
-
BUSINESS Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
November 26, 2018
-
REGULATORY MHLW Eyes Drastic Change to Cost Effective Analysis Flow, Enhanced Discussions Upfront
November 22, 2018
-
REGULATORY MHLW Proposes Quarterly Product Selections, Price Tweaks for CEA Scheme: Chuikyo
November 22, 2018
-
BUSINESS Pfizer’s ALK Inhibitor Lorbrena, Shire’s HAE Drug Now Available in Japan
November 21, 2018
-
BUSINESS Mitsubishi Tanabe Cuts FY2020 Targets in 5-Year Biz Plan on Flagging Royalty, Development Delay
November 21, 2018
-
BUSINESS 3 Japan Generic Majors Log 6% Growth in Combined April-September Sales despite Price Revision
November 20, 2018
-
BUSINESS 4 Major Wholesalers See 46.1% Increase in 1st Half Operating Profit due to Reductions in Yakkasa and SGA Costs
November 19, 2018
-
BUSINESS AstraZeneca Japan Set to Roll Out 4 New Treatments Every Year through 2021: Chief
November 16, 2018
-
REGULATORY Keytruda’s MSI-H Cancer Use Up for MHLW Panel Review Nov. 29; Wider Hemlibra Indication, 1st Line Tecentriq Also on Agenda
November 16, 2018
-
BUSINESS Hib Vaccine Wind-Up, Development Flop Trigger GSK, Daiichi Sankyo to Shutter JV
November 15, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…